COMPARE · Data as of August 21, 2026
LIVN vs PODD
Verdict: Side-by-side breakdown using the Bull Rankings model. LIVN scored 69.8, PODD scored 77.6 — PODD leads.
Compare another set
LIVN
LivaNova PLC
69.8
$78.74 · $4.3B
fundamentals as of
Score gap
7.8
PODD leads
PODD
Insulet Corporation
77.6
$148.16 · $10.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestLIVN23.2x
- Fastest growthPODD+29.4%
- Strongest balance sheetLIVN0.27
- Highest qualityPODD73 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
LIVN
stronger →← stronger
PODD
61
Qualityreturns · margins · balance sheet
73
82
Growthrevenue & earnings expansion
95
67
Valuevaluation vs sector peers
67
PODD is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
LIVN
PODD
$148mC
FCF
$294mC
+12.4%B+
Rev
+29.4%A-
0.27B
D/E
0.67C+
23.2xB+
P/E
27.8xB
0.93B+
PEG
1.52C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
LIVN
PODD
62% above
Price vs fair valuelower is cheaper
83% above
~17%/yr
Growth the price implies10-yr FCF · lower = less priced in
~27%/yr
-42%
1-yr DCF upside
-55%
-38%
5-yr DCF upside
-45%
-33%
10-yr DCF upside
-27%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
The companies
LIVNLivaNova PLC
Why now
Medical Devices · market cap $4.3b. 8% off the 52-week high of $85.76. Revenue growing +12%, comfortably above the S&P median. PEG 0.93 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $88.80 (implying +13% upside).
Moat
Net margin 13% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
PODDInsulet Corporation
Why now
Medical Devices · market cap $10.3b. Down 58% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +29% — in hypergrowth territory. 22 sell-side analysts rate this a Buy with a mean 1-yr target of $171.91 (implying +16% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Down 58% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where LIVN and PODD diverge
On the headline score the gap is 7.8 points in favor of PODD. The widest single difference is Growth, where PODD leads by 12.9 points.
- GrowthLIVN 82.4 · PODD 95.3PODD +12.9
- QualityLIVN 61.5 · PODD 73.3PODD +11.8
- ValueLIVN 66.9 · PODD 66.7level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.